Epigallocatechin gallate increases the formation of cytosolic lipid droplets and decreases the secretion of apoB-100 VLDL

Journal of Lipid Research

Volumn 47, Issue 1, 2006, Pages 67-77

  Li, Lu ^a   Stillemark Billton, Pia ^a   Beck, Caroline ^a   Boström, Pontus ^a   Andersson, Linda ^a   Rutberg, Mikael ^a   Ericsson, Johanna ^a   Magnusson, Björn ^a   Marchesan, Denis ^a   Ljungberg, Anna ^a   Borén, Jan ^a   Olofsson, Sven Olof ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Apolipoprotein B 100; Intracellular degradation; Low density lipoprotein receptor; Ubiquitination

Indexed keywords

APOLIPOPROTEIN B100; EPIGALLOCATECHIN GALLATE; FAT DROPLET; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; LIPID METABOLISM; LIPID PEROXIDATION; LIPID STORAGE; LIVER CYTOSOL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN DEGRADATION; PROTEIN SECRETION; TRIACYLGLYCEROL BLOOD LEVEL; UBIQUITINATION;

ADIPOCYTES; ANIMALS; APOLIPOPROTEIN B-100; APOLIPOPROTEINS B; BASE SEQUENCE; CATECHIN; CELL LINE; CYTOSOL; DNA, COMPLEMENTARY; HEPARIN; HUMANS; LIPID METABOLISM; LIPIDS; LIPOPROTEINS; LIPOPROTEINS, VLDL; MEMBRANE PROTEINS; MICE; MICE, TRANSGENIC; NIH 3T3 CELLS; RATS; RECEPTORS, LDL; RECOMBINANT PROTEINS;

EID: 30844433516     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M500424-JLR200     Document Type: Article

References (42)

1. Browning, J. D., and J. D. Horton. 2004. Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest. 114: 147-152.
2. den Boer, M., P. J. Voshol, F. Kuipers, L. M. Havekes, and J. A. Romijn. 2004. Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models. Arterioscler. Thromb. Vasc. Biol. 24: 644-649.
3. Donnelly, K. L., C. I. Smith, S. J. Schwarzenberg, J. Jessurun, M. D. Boldt, and E. J. Parks. 2005. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 115: 1343-1351.
4. Wiggins, D., and G. F. Gibbons. 1992. The lipolysis/esterification cycle of hepatic triacylglycerol. Its role in the secretion of very-low-density lipoprotein and its response to hormones and sulphonylureas. Biochem. J. 284: 457-462.
5. Salter, A. M., D. Wiggins, V. A. Sessions, and G. F. Gibbons. 1998. The intracellular triacylglycerol/fatty acid cycle: a comparison of its activity in hepatocytes which secrete exclusively apolipoprotein (apo) B100 very-low-density lipoprotein (VLDL) and in those which secrete predominantly apoB48 VLDL. Biochem. J. 332: 667-672.
6. Gibbons, G. F., K. Islam, and R. J. Pease. 2000. Mobilisation of triacylglycerol stores. Biochim. Biophys. Acta. 1483: 37-57.
7. Murphy, D. J., and J. Vance. 1999. Mechanisms of lipid-body formation. Trends Biochem. Sci. 24: 109-115.
8. Brown, D. A. 2001. Lipid droplets: proteins floating on a pool of fat. Curr. Biol. 11: R446-R449.
9. Marchesan, D., M. Rutberg, L. Andersson, L. Asp, T. Larsson, J. Boren, B. R. Johansson, and S. O. Olofsson. 2003. A phospholipase D-dependent process forms lipid droplets containing caveolin, adipocyte differentiation-related protein, and vimentin in a cell-free system. J. Biol. Chem. 278: 27293-27300.
10. Bostrom, P., M. Rutberg, J. Ericsson, P. Holmdahl, L. Andersson, M. A. Frohman, J. Boren, and S. O. Olofsson. 2005. Cytosolic lipid droplets increase in size by microtubule-dependent complex formation. Arterioscler. Thromb. Vasc. Biol. 25: 1945-1951.
11. Olofsson, S-O., L. Asp, and J. Borén. 1999. The assembly and secretion of apolipoprotein B-containing lipoproteins. Curr. Opin. Lipidol. 10: 341-346.
12. Davidson, N. O., and G. S. Shelness. 2000. APOLIPOPROTEIN B: mRNA editing, lipoprotein assembly, and presecretory degradation. Annu. Rev. Nutr. 20: 169-193.
13. Olofsson, S-O., P. Stillemark-Billton, and L. Asp. 2000. The intracellular assembly of VLDL - a process that consists of two major steps that occur in separate cell compartments. Trends Cardiovasc. Med. 10: 338-345.
14. Gibbons, G. F., D. Wiggins, A. M. Brown, and A. M. Hebbachi. 2004. Synthesis and function of hepatic very-low-density lipoprotein. Biochem. Soc. Trans. 32: 59-64.
15. Olofsson, S-O., and L. Asp. 2005. The assembly of very low density lipoproteins (VLDL) in the liver. In Lipid and Atherosclerosis: Advances in Translational Medicine. C. J. Packard and D. Rader, editors. Taylor and Francis, London. 1-15.
16. Olofsson, S., and J. Borén. 2005. Apolipoprotein B: a clinical important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis. J. Intern. Med. 258: 395-410.
17. Stillemark-Billton, P., C. Beck, J. Boren, and S. O. Olofsson. 2005. Relation of the size and intracellular sorting of apoB to the formation of VLDL 1 and VLDL 2. J. Lipid Res. 46: 104-114.
18. Fisher, E. A., M. Pan, X. Chen, X. Wu, H. Wang, H. Jamil, J. D. Sparks, and K. J. Williams. 2001. The triple threat to nascent apolipoprotein B. Evidence for multiple, distinct degradative pathways. J. Biol. Chem. 276: 27855-27863.
19. Fisher, E. A., and H. N. Ginsberg. 2002. Complexity in the secretory pathway: the assembly and secretion of apolipoprotein B-containing lipoproteins. J. Biol. Chem. 277: 17377-17380.
20. Miura, Y., T. Chiba, I. Tomita, H. Koizumi, S. Miura, K. Umegaki, Y. Hara, M. Ikeda, and T. Tomita. 2001. Tea catechins prevent the development of atherosclerosis in apoprotein E-deficient mice. J. Nutr. 131: 27-32.
21. Kim, S. Y., B. H. Ahn, K. J. Min, Y. H. Lee, E. H. Joe, and S. Min do. 2004. Phospholipase D isozymes mediate epigallocatechin gallate-induced cyclooxygenase-2 expression in astrocyte cells. J. Biol. Chem. 279: 38125-38133.
22. Yee, W. L., Q. Wang, T. Agdinaoay, K. Dang, H. Chang, A. Grandinetti, A. A. Franke, and A. Theriault. 2002. Green tea catechins decrease apolipoprotein B-100 secretion from HepG2 cells. Mol. Cell. Biochem. 229: 85-92.
23. Borén, J., S. Rustaeus, and S-O. Olofsson. 1994. Studies on the assembly of apolipoprotein B-100- and B-48-containing very low density lipoproteins in McA-RH7777 cells. J. Biol. Chem. 269: 25879-25888.
24. Sonka, M., V. Hlavac, and R. Boyle. 1999. Image Processing, Analysis and Machine Vision. International Thomson Publishing, Pacific Grove, CA.
25. Wettesten, M., K. Boström, G. Bondjers, M. Jarfeldt, P-I. Norfeldt, M. Carrella, O. Wiklund, J. Borén, and S-O. Olofsson. 1985. Pulsechase studies of the synthesis of apolipoprotein B in a human hepatoma cell line, Hep G2. Eur. J. Biochem. 149: 461-466.
26. Rustaeus, S., P. Stillemark, K. Lindberg, D. Gordon, and S-O. Olofsson. 1998. The microsomal triglyceride transfer protein catalyzes the post-translational assembly of apolipoprotein B-100 very low density lipoprotein in McA-RH7777 cells. J. Biol. Chem. 273: 5196-5203.
27. Andersson, M., M. Wettesten, J. Borén, A. Magnusson, A. Sjöberg, S. Rustaeus, and S-O. Olofsson. 1994. Purification of diacylglycerol: acyltransferase from rat liver to near homogeneity. J. Lipid Res. 35: 535-545.
28. Moon, A., and W. J. Rhead. 1987. Complementation analysis of fatty acid oxidation disorders. J. Clin. Invest. 79: 59-64.
29. Steiner, M. R., and R. L. Lester. 1972. In vitro studies of phospholipid biosynthesis in Saccharomyces cerevisiae. Biochim. Biophys. Acta. 260: 222-243.
30. Fisher, E. A., M. Zhou, D. M. Mitchell, X. Wu, S. Omura, H. Wang, A. L. Goldberg, and H. N. Ginsberg. 1997. The degradation of apolipoprotein B 100 is mediated by the ubiquitin-proteasome pathway and involves heat shock protein 70. J. Biol. Chem. 272: 20427-20434.
31. Zhou, M., E. A. Fisher, and H. N. Ginsberg. 1998. Regulated cotranslational ubiquitination of apolipoprotein B 100. J. Biol. Chem. 273: 24649-24653.
32. Funatsu, T., K. Suzuki, M. Goto, Y. Arai, H. Kakuta, H. Tanaka, S. Yasuda, M. Ida, S. Nishijima, and K. Miyata. 2001. Prolonged inhibition of cholesterol synthesis by atorvastatin inhibits apo B-100 and triglyceride secretion from HepG2 cells. Atherosclerosis. 157: 107-115.
33. Bursill, C., P. D. Roach, C. D. Bottema, and S. Pal. 2001. Green tea upregulates the low-density lipoprotein receptor through the sterol-regulated element binding protein in HepG2 liver cells. J. Agric. Food Chem. 49: 5639-5645.
34. Horton, J. D., H. Shimano, R. L. Hamilton, M. S. Brown, and J. L. Goldstein. 1999. Disruption of LDL receptor gene in transgenic SREBP-1a mice unmasks hyperlipidemia resulting from production of lipid-rich VLDL. J. Clin. Invest. 103: 1067-1076.
35. Twisk, J., D. L. Gillian-Daniel, A. Tebon, L. Wang, P. H. Barrett, and A. D. Attie. 2000. The role of the LDL receptor in apolipoprotein B secretion. J. Clin. Invest. 105: 521-532.
36. Gillian-Daniel, D. L., P. W. Bates, A. Tebon, and A. D. Attie. 2002. Endoplasmic reticulum localization of the low density lipoprotein receptor mediates presecretory degradation of apolipoprotein B. Proc. Natl. Acad. Sci. USA. 99: 4337-4342.
37. Larsson, S. L., J. Skogsberg, and J. Bjorkegren. 2004. The low density lipoprotein receptor prevents secretion of dense apoB100-containing lipoproteins from the liver. J. Biol. Chem. 279: 831-836.
38. Kao, Y. H., R. A. Hiipakka, and S. Liao. 2000. Modulation of endocrine systems and food intake by green tea epigallocatechin gallate. Endocrinology. 141: 980-987.
39. Mitchell, D. M., M. Zhou, R. Pariyarath, H. Wang, J. D. Aitchison, H. N. Ginsberg, and E. A. Fisher. 1998. Apoprotein B 100 has a prolonged interaction with the translocon during which its lipidation and translocation change from dependence on the microsomal triglyceride transfer protein to independence. Proc. Natl. Acad. Sci. USA. 95: 14733-14738.
40. Liang, J-S., X. Wu, E. A. Fisher, and H. N. Ginsberg. 2000. The amino-terminal domain of apolipoprotein B does not undergo retrograde translocation from the endoplasmic reticulum to the cytosol. Proteasomal degradation of nascent apolipoprotein B begins at the carboxyl terminus of the protein, while apolipoprotein B is still in its original translocon. J. Biol. Chem. 275: 32003-32010.
41. Pariyarath, R., H. Wang, J. D. Aitchison, H. N. Ginsberg, W. J. Welch, A. E. Johnson, and E. A. Fisher. 2001. Co-translational interactions of apoprotein B with the ribosome and translocon during lipoprotein assembly or targeting to the proteasome. J. Biol. Chem. 276: 541-550.
42. Lambert, J. D., M. J. Lee, H. Lu, X. Meng, J. J. Hong, D. N. Seril, M. G. Sturgill, and C. S. Yang. 2003. Epigallocatechin-3-gallate is absorbed but extensively glucuronidated following oral administration to mice. J. Nutr. 133: 4172-4177.